logo
Share SHARE
FONT-SIZE Plus   Neg

Peregrine Cites Clinical Data To Highlight Potential Of Bavituximab

Clinical-stage biopharmaceutical company Peregrine Pharmaceuticals Inc (PPHM) Wednesday highlighted positive data from two Phase I investigator-sponsored trials and one preclinical study while evaluating the potential of bavituximab when combined with standard approved therapies in breast, liver and prostate cancers.

The company stated that in a Phase I trial of bavituximab with paclitaxel in five evaluable patients with HER-2 negative metastatic breast cancer, two patients achieved a complete tumor response, one achieved a partial response, and two had progressive disease according to Response Evaluation Criteria In Solid Tumors measurement criteria.

Additionally, the company presented data from a Phase I/II trial investigating bavituximab with sorafenib in patients with advanced hepatocellular carcinoma, in which no dose-limiting toxicities or serious adverse events were observed in the first phase of the trial.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Senate Republicans released a draft of their version of legislation to repeal and replace Obamacare on Thursday, with a vote on the 142-page bill expected as soon as next week. The bill, called the Better Care Reconciliation Act, repeals Obamacare's individual and employer mandates as well as the... A local cable and broadband provider in Texas has filed a lawsuit against Comcast Corp., alleging that the cable giant and its contractors drove it out of business by severing its business cable lines after it rejected Comcast's buyout offer. The lawsuit was filed last week in Harris County, Texas, court by Anthony Luna, owner of Telecom Cable LLC. John Oliver, the host of HBO's Sunday Show "Last Week Tonight," HBO and Time Warner have been sued by coal baron Robert Murray for mocking him and his coal company on the show's most recent episode. Murray had previously sent the show its first cease-and-desist letter.
comments powered by Disqus
Follow RTT